Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$127.29 USD

127.29
5,452,778

+1.10 (0.87%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $127.29 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons to Add Cardinal Health Stock to Your Portfolio Now

by Zacks Equity Research

CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.

Zacks Equity Research

ResMed Gains 37.8% in a Year: What's Driving the Stock?

by Zacks Equity Research

RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning.

Zacks Equity Research

Here's Why You Should Add MMSI Stock to Your Portfolio Now

by Zacks Equity Research

Merit Medical's strong product portfolio raises optimism about the stock.

Zacks Equity Research

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device

by Zacks Equity Research

INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.

Zacks Equity Research

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

by Zacks Equity Research

RVTY's strong product portfolio raises optimism about the stock.

Zacks Equity Research

Abbott (ABT) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Abbott (ABT) stood at $112.80, denoting a -1.9% change from the preceding trading day.

Zacks Equity Research

Here's Why You Should Retain Integer Holdings Stock in Your Portfolio

by Zacks Equity Research

ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.

Harshit Gupta headshot

5 MedTech Stocks That Are Poised to Beat the Market in 2025

by Harshit Gupta

Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.

Zacks Equity Research

HealthEquity Gains 46.8% in a Year: What's Driving the Stock?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

by Zacks Equity Research

ECL continues to gain from its strong segmental performance and improved operating margin.

Zacks Equity Research

Growing Biosimilars Business, New Partnerships Support ABT Stock

by Zacks Equity Research

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Zacks Equity Research

OSUR Stock Rises Following the Acquisition of Sherlock Biosciences

by Zacks Equity Research

OraSure announces acquisition of Sherlock Biosciences to strengthen its molecular diagnostics portfolio.

Urmimala Biswas headshot

Is Abbott Stock Worth Buying at a Discounted P/S Valuation?

by Urmimala Biswas

Abbott's strong market position, promising growth prospects and consistent share gains make it a compelling pick for investors.

Zacks Equity Research

Abbott (ABT) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $114.76, moving +0.39% from the previous trading session.

Zacks Equity Research

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA

by Zacks Equity Research

GKOS announces New Drug Application submission for its Epioxa to the FDA.

Zacks Equity Research

Integer Holdings Gains 34.4% in One Year: What's Driving the Stock?

by Zacks Equity Research

ITGR shares gain on the back of growth in the Medical segment. However, dependence on third-party suppliers is concerning.

Zacks Equity Research

Abbott (ABT) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

The latest trading day saw Abbott (ABT) settling at $114.31, representing a +0.07% change from its previous close.

Zacks Equity Research

Ensign Expands Footprint With Buyout of Eight Healthcare Facilities

by Zacks Equity Research

ENSG agrees to buy eight healthcare facilities from Providence Home and Community Care, expanding its footprint.

Zacks Equity Research

Merit Medical Stock Rises Following FDA Nod for WRAPSODY Device

by Zacks Equity Research

MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis.

Urmimala Biswas headshot

Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?

by Urmimala Biswas

MDT stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.

Zacks Equity Research

SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA

by Zacks Equity Research

Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty.

Zacks Equity Research

Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

by Zacks Equity Research

WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.

Zacks Equity Research

The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories

by Zacks Equity Research

Veracyte, Omnicell, Masimo and Abbott Laboratories are included in this Analyst Blog.